Jefferies Global Healthcare Conference
Logotype for IDEAYA Biosciences Inc

IDEAYA Biosciences (IDYA) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for IDEAYA Biosciences Inc

Jefferies Global Healthcare Conference summary

17 Nov, 2026

Darovasertib and regulatory path

  • NDA submitted at the end of Q3; acceptance anticipated this quarter, with expedited review expected under Fast Track and RTOR.

  • Analysts project a metastatic uveal melanoma launch in H1 next year; launch preparation is among the next 6–12-month catalysts.

  • OS interim analysis projected for mid-next year, with ~6 months of added follow-up in the NDA versus topline data; the OS data are expected to remain early.

  • The mechanism targets activating GNAQ/11 mutations and is viewed as not specifically linked to HLA-A2; a broader metastatic population and NCCN strategy are being pursued.

  • After metastatic approval, published neoadjuvant data will be submitted for NCCN compendia review; inclusion in at least one enucleation- or plaque-eligible subset is expected.

Clinical development and enrollment

  • The pivotal adjuvant study with Servier dosed its first patient in September; enrollment is on track, with further timing visibility potentially next year.

  • IDE849's global Phase I/II update is expected to include ideally >30 patients, roughly split between SCLC and NEC, including post-IMDELLTRA patients.

  • Refractory NEC plans include a randomized Phase III across multiple subtypes and a ~90-patient single-arm Phase II in GEP-NEC; study launches are targeted by year-end.

  • SCLC Phase III strategy focuses on the post-IMDELLTRA setting; frontline development is oriented toward induction with a differentiated combination, potentially anchored by a T-cell engager.

Pipeline updates and combinations

  • PRMT5 showed exposures exceeding target EC90 coverage, Grade 3+ AE rates in the single-digit range, and a favorable early safety profile; no observed CYP3A4 drug interaction supports combination use.

  • PRMT5–MAT2A dose optimization shifted expansion timing to H1 next year; lung cancer is the focus, with an ideal response-rate threshold of 40%+ in second-line patients.

  • First patient dosing for the PRMT5–Roche pan-RAS combination in PDAC is targeted by year-end; if data are positive, a registrational-study plan could be considered toward the end of next year.

  • IDE892 plus pan-RAS data are targeted for next year, with clinical proof of concept, safety, efficacy, and absence of drug interaction as key questions.

  • KAT6/7 showed early response activity, including in a fifth-line breast cancer patient; 2027 updates will assess monotherapy response, with breast cancer and CRC among areas of interest.

  • IDE101 targets CDKN2A deficiency, estimated at ~70% of pancreatic cancer, and is projected to enter the clinic in H1 next year; combinations with pan-RAS or PRMT5 are being considered.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from IDEAYA Biosciences